XENE Xenon Pharmaceuticals Inc Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:59
Jul 27
Jul 27
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE acquisition, celebrating broad sector gains without explicit forward calls on most names.
LOW
00:07
Jul 27
Jul 27
Buy XENE as a second-tier derisked/M&A candidate; speaker also names it as favorite in the neuro disease space, suggesting pipeline conviction alongside M&A optionality.
MED
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
About XENE Analyst Coverage
Buzzberg tracks XENE (Xenon Pharmaceuticals Inc) across 1 sources. 2 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (40%). 5 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: seedy19tron.